NEW YORK, Aug. 5 /PRNewswire-FirstCall/ -- NeoStem, Inc. announced today that the new Southern Florida stem cell collection center located in Coral Gables, a suburb of Miami, is targeted to open in September. The center is being opened pursuant to an agreement with CelVida LLC. With the opening of this center, NeoStem has secured a key geographic stronghold in an area that is open to a large U.S. market as well as a growing sophisticated South American presence.
Chester Amedia, Jr. MD, FACP, is the Founder and President of CelVida LLC and has had extensive business and patient care experience in the fields of disease management and extracorporeal therapy. “We are thrilled to be part of what many believe to be an emerging “Stem Cell Revolution” and have chosen to strategically align with NeoStem to provide individuals looking for a proactive approach to their future medical care the opportunity to have their stem cells collected and preserved for use in the future in the event of medical need,” stated Dr. Amedia. “It is estimated that by 2017 there will be as many as 2 million annual procedures that will include stem cell based therapies for diabetes, orthopedic injuries, cardiovascular disease, inflammatory diseases, among others.”
“We are thrilled to be working with such an accomplished physician who has demonstrated success in building a flourishing medical business. We believe that patient specific stem cell collection and storage one day will be viewed as being as routine as securing health insurance. We continue to see an abundance of evidence in the scientific literature as data from clinical trials supports the proposition that autologous adult stem cell therapies are emerging as an important measure in repairing degenerated, damaged and diseased tissue (the three “Ds” of aging),” said Robin Smith, MD, CEO of NeoStem.
About CelVida LLC
CelVida was organized to develop a network of personal self-care centers in key metropolitan markets around the country. The CelVida network intends to make the simple process of stem cell collection and storage available to individuals proactively seeking healthcare options that embrace new technologies.
About NeoStem, Inc.
NeoStem is managing a network of adult stem cell collection centers, enabling people (through its proprietary technology) to donate and store their own (autologous) stem cells when they are young and/or relatively healthy for their personal use in times of future medical need. The Company has also recently entered into research and development through the acquisition of a worldwide exclusive license to technology to identify and isolate VSELs (very small embryonic-like stem cells), which have been shown to have several physical characteristics that are generally found in embryonic stem cells.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the “Risk Factors” described in the Company’s periodic filings with the Securities and Exchange Commission.
CONTACT: Robin Smith, Chief Executive Officer of NeoStem, Inc.,
+1-212-584-4180, rsmith@neostem.com
Web site: http://www.neostem.com/
